Details of the Drug

General Information of Drug (ID: DM5PDRB)

Drug Name

Amikacin

Synonyms

Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]
Tuberculosis	1B10-1B1Z	Investigative	[2]

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 4

Molecular Weight (mw)

585.6

Topological Polar Surface Area (xlogp)

-7.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance: The renal clearance of drug is 94 mL/min [4]
Elimination: In adults with normal renal function, 94-98% of a single IM or IV dose of amikacin is excreted unchanged by glomerular filtration in the kidney within 24 hours [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 25.61415 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.88% [5]
Vd: The volume of distribution (Vd) of drug is 24 L [4]

Chemical Identifiers

Formula: C22H43N5O13
IUPAC Name: (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
Canonical SMILES: C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
InChI: InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
InChIKey: LKCWBDHBTVXHDL-RMDFUYIESA-N

Cross-matching ID

PubChem CID: 37768
ChEBI ID: CHEBI:2637
CAS Number: 37517-28-5
DrugBank ID: DB00479
TTD ID: D0Y3MO
INTEDE ID: DR2167
ACDINA ID: D00832

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)	TTQ8KVI	F4NA87_STAAU	Binder	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Aminoglycoside O-phosphotransferase (aphA6)	DEWPAJD	KKA6_ACIBA	Substrate	[8]
Endoglucanase A (EGA)	DE1C8Q4	A0A660DUI5_9LACO	Substrate	[9]
Endoglucanase Y (EGY)	DE2AZTG	A0A256VAC0_LACRE	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amikacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Cefotetan	DM07TX3	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefotetan.	Bacterial infection [1A00-1C4Z]	[20]
Kanamycin	DM2DMPO	Moderate	Increased risk of ototoxicity by the combination of Amikacin and Kanamycin.	Bacterial infection [1A00-1C4Z]	[21]
Ceftizoxime	DM3VOGS	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Ceftizoxime.	Bacterial infection [1A00-1C4Z]	[20]
Cefoperazone	DM53PV8	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefoperazone.	Bacterial infection [1A00-1C4Z]	[20]
Cefprozil	DM7DSYP	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefprozil.	Bacterial infection [1A00-1C4Z]	[20]
Ceftriaxone	DMCEW64	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Ceftriaxone.	Bacterial infection [1A00-1C4Z]	[20]
Streptomycin	DME1LQN	Moderate	Increased risk of ototoxicity by the combination of Amikacin and Streptomycin.	Bacterial infection [1A00-1C4Z]	[21]
Cefepime	DMHVWIK	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefepime.	Bacterial infection [1A00-1C4Z]	[20]
Cefpodoxime	DMJUNY5	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[20]
Gentamicin	DMKINJO	Moderate	Increased risk of ototoxicity by the combination of Amikacin and Gentamicin.	Bacterial infection [1A00-1C4Z]	[21]
Cefotaxime	DMMKHBJ	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefotaxime.	Bacterial infection [1A00-1C4Z]	[20]
Rabeprazole	DMMZXIW	Moderate	Increased risk of hypomagnesemia by the combination of Amikacin and Rabeprazole.	Bacterial infection [1A00-1C4Z]	[22]
Cefazolin	DMPDYFR	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefazolin.	Bacterial infection [1A00-1C4Z]	[20]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Netilmicin.	Bacterial infection [1A00-1C4Z]	[21]
Cefonicid	DMTX2BH	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefonicid.	Bacterial infection [1A00-1C4Z]	[20]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Tobramycin.	Bacterial infection [1A00-1C4Z]	[21]
Cefradine	DMUNSWV	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefradine.	Bacterial infection [1A00-1C4Z]	[23]
Cefixime	DMY60I8	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefixime.	Bacterial infection [1A00-1C4Z]	[20]
Cefoxitin	DMYTXVR	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefoxitin.	Bacterial infection [1A00-1C4Z]	[20]
-----------


⏷ Show the Full List of 19 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Amikacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Amikacin caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[21]
Cefuroxime	DMSIMD8	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefuroxime.	Acute bronchitis [CA42]	[20]
Magnesium Sulfate	DMVEK07	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Magnesium Sulfate.	Acute pain [MG31]	[24]
Framycetin	DMF8DNE	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Framycetin.	Alcoholic liver disease [DB94]	[21]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Inotersen.	Amyloidosis [5D00]	[25]
Cefamandole	DMNEXZF	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cefamandole.	Anaerobic bacterial infection [1A00-1A09]	[20]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of hypocalcemia by the combination of Amikacin and Etidronic acid.	Bone paget disease [FB85]	[26]
Risedronate	DM5FLTY	Moderate	Increased risk of hypocalcemia by the combination of Amikacin and Risedronate.	Bone paget disease [FB85]	[26]
Alendronate	DMY2KX9	Moderate	Increased risk of hypocalcemia by the combination of Amikacin and Alendronate.	Bone paget disease [FB85]	[26]
Mannitol	DMSCDY9	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Mannitol.	Bronchiectasis [CA24]	[27]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Iodipamide.	Cholelithiasis [DC11]	[28]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Phenylbutazone.	Chronic pain [MG30]	[29]
Ketoprofen	DMRKXPT	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Ketoprofen.	Chronic pain [MG30]	[29]
Oxaliplatin	DMQNWRD	Moderate	Decreased renal excretion of Amikacin caused by Oxaliplatin mediated nephrotoxicity.	Colorectal cancer [2B91]	[30]
Atracurium	DM42HXN	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Atracurium.	Corneal disease [9A76-9A78]	[31]
Mivacurium	DM473VD	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Mivacurium.	Corneal disease [9A76-9A78]	[31]
Pancuronium	DMB0VY8	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Pancuronium.	Corneal disease [9A76-9A78]	[31]
Tubocurarine	DMBZIVP	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Tubocurarine.	Corneal disease [9A76-9A78]	[31]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Methoxyflurane.	Corneal disease [9A76-9A78]	[25]
Mycophenolic acid	DMU65NK	Moderate	Altered absorption of Amikacin due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[32]
Ethacrynic acid	DM60QMR	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Ethacrynic acid.	Essential hypertension [BA00]	[33]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Mefenamic acid.	Female pelvic pain [GA34]	[29]
Amphotericin B	DMTAJQE	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Amphotericin B.	Fungal infection [1F29-1F2F]	[34]
Dexlansoprazole	DM1DBV5	Moderate	Increased risk of hypomagnesemia by the combination of Amikacin and Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[22]
Furosemide	DMMQ8ZG	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Furosemide.	Heart failure [BD10-BD1Z]	[27]
Bumetanide	DMRV7H0	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Bumetanide.	Heart failure [BD10-BD1Z]	[27]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[21]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Balsalazide.	Indeterminate colitis [DD72]	[35]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[36]
Ibandronate	DM0QZBN	Moderate	Increased risk of hypocalcemia by the combination of Amikacin and Ibandronate.	Low bone mass disorder [FB83]	[37]
Clofarabine	DMCVJ86	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Clofarabine.	Mature B-cell lymphoma [2A85]	[38]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Exjade.	Mineral absorption/transport disorder [5C64]	[39]
Neostigmine	DM6T2J3	Moderate	Additive neuromuscular blocking effects by the combination of Amikacin and Neostigmine.	Myasthenia gravis [8C6Y]	[31]
Pyridostigmine	DM8HO1L	Moderate	Additive neuromuscular blocking effects by the combination of Amikacin and Pyridostigmine.	Myasthenia gravis [8C6Y]	[31]
Rofecoxib	DM3P5DA	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Rofecoxib.	Osteoarthritis [FA00-FA05]	[29]
Valdecoxib	DMAY7H4	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Valdecoxib.	Osteoarthritis [FA00-FA05]	[29]
Diclofenac	DMPIHLS	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Diclofenac.	Osteoarthritis [FA00-FA05]	[29]
Naproxen	DMZ5RGV	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Naproxen.	Osteoarthritis [FA00-FA05]	[29]
Carboplatin	DMG281S	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Carboplatin.	Ovarian cancer [2C73]	[40]
Aspirin	DM672AH	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Aspirin.	Pain [MG30-MG3Z]	[36]
Etodolac	DM6WJO9	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Etodolac.	Pain [MG30-MG3Z]	[29]
Diflunisal	DM7EN8I	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Diflunisal.	Pain [MG30-MG3Z]	[29]
Ibuprofen	DM8VCBE	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Ibuprofen.	Pain [MG30-MG3Z]	[29]
Piroxicam	DMTK234	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Piroxicam.	Pain [MG30-MG3Z]	[29]
Esomeprazole	DM7BN0X	Moderate	Increased risk of hypomagnesemia by the combination of Amikacin and Esomeprazole.	Peptic ulcer [DA61]	[41]
Pemetrexed	DMMX2E6	Moderate	Decreased renal excretion of Amikacin caused by Pemetrexed mediated nephrotoxicity.	Pleural mesothelioma [2C26]	[42]
Choline salicylate	DM8P137	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[29]
Bromfenac	DMKB79O	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Bromfenac.	Postoperative inflammation [1A00-CA43]	[29]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Everolimus.	Renal cell carcinoma [2C90]	[43]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Temsirolimus.	Renal cell carcinoma [2C90]	[43]
Salsalate	DM13P4C	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Salsalate.	Rheumatoid arthritis [FA20]	[29]
Meloxicam	DM2AR7L	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Meloxicam.	Rheumatoid arthritis [FA20]	[36]
Sulindac	DM2QHZU	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Sulindac.	Rheumatoid arthritis [FA20]	[29]
Celecoxib	DM6LOQU	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Celecoxib.	Rheumatoid arthritis [FA20]	[29]
Oxaprozin	DM9UB0P	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Oxaprozin.	Rheumatoid arthritis [FA20]	[29]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Flurbiprofen.	Rheumatoid arthritis [FA20]	[29]
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Sulfasalazine.	Rheumatoid arthritis [FA20]	[35]
Fenoprofen	DML5VQ0	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Fenoprofen.	Rheumatoid arthritis [FA20]	[29]
Tolmetin	DMWUIJE	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Tolmetin.	Rheumatoid arthritis [FA20]	[29]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[36]
Cephapirin	DMV2JNY	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Cephapirin.	Sepsis [1G40-1G41]	[23]
Ifosfamide	DMCT3I8	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[21]
Pipecuronium	DM5F84A	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Pipecuronium.	Tonus and reflex abnormality [MB47]	[31]
Doxacurium	DMKE7L9	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Doxacurium.	Tonus and reflex abnormality [MB47]	[31]
Vecuronium	DMP0UK2	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Vecuronium.	Tonus and reflex abnormality [MB47]	[31]
Cisatracurium	DMUZPJ5	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Cisatracurium.	Tonus and reflex abnormality [MB47]	[31]
Rocuronium	DMY9BMK	Major	Additive neuromuscular blocking effects by the combination of Amikacin and Rocuronium.	Tonus and reflex abnormality [MB47]	[31]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Sirolimus.	Transplant rejection [NE84]	[43]
Mycophenolate mofetil	DMPQAGE	Moderate	Altered absorption of Amikacin due to GI flora changes caused by Mycophenolate mofetil.	Transplant rejection [NE84]	[32]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Amikacin and Tacrolimus.	Transplant rejection [NE84]	[43]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Olsalazine.	Ulcerative colitis [DD71]	[35]
Plazomicin	DMKMBES	Moderate	Increased risk of ototoxicity by the combination of Amikacin and Plazomicin.	Urinary tract infection [GC08]	[21]
Valaciclovir	DMHKS94	Moderate	Increased risk of nephrotoxicity by the combination of Amikacin and Valaciclovir.	Virus infection [1A24-1D9Z]	[25]
-----------


⏷ Show the Full List of 73 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium citrate anhydrous	E00102	6224	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Cholesterol	E00092	5997	Emollient; Emulsifying agent
Sulfuric acid	E00045	1118	Acidulant
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Sodium metabisulfite	E00444	656671	Antimicrobial preservative; Antioxidant
Water	E00035	962	Solvent
1,2-Distearoyl-sn-glycero-3-phosphocholine	E00710	Not Available	Other agent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Amikacin eq 250mg injectable	eq 250mg	Injectable	Injection
Amikacin 590 mg/8.4 ml injectable	590 mg/8.4 ml	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
2	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3	BDDCS applied to over 900 drugs
4	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9.
8	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
9	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
10	The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.
11	Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9.
12	Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6.
13	Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5.
14	Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
15	Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
16	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17	Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16.
18	Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
19	Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.
20	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
21	Cerner Multum, Inc. "Australian Product Information.".
22	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
23	Engle JE, Drago J, Carlin B, Schoolwerth AC "Letter: Reversible acute renal failure after cephalothin." Ann Intern Med 83 (1975): 232-3. [PMID: 1147461]
24	Piper BJ, Alinea AA, Wroblewski JR, et al. A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of Therapeutics. Pharmacy (Basel). 2019;8(1):1. Published 2019 Dec 20. [PMID: 31861770]
25	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26	Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
27	Athlin L, Domellof L, Holm S "Gentamicin treatment in severe surgical infections: serum levels, interactions, toxicity and efficacy." Acta Chir Scand 147 (1981): 225-30. [PMID: 7034430]
28	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
29	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
30	Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
31	Burkett L, Bikhazi GB, Thomas KC Jr, Rosenthal DA, Wirta MG, Foldes FF "Mutual potentiation of the neuromuscular effects of antibiotics and relaxants." Anesth Analg 58 (1979): 107-15. [PMID: 571233]
32	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
33	Bates DE, Beaumont SJ, Baylis BW "Ototoxicity induced by gentamicin and furosemide." Ann Pharmacother 36 (2002): 446-51. [PMID: 11895059]
34	Churchill DN, Seely J "Nephrotoxicity associated with combined gentamicin - amphotericin B therapy." Nephron 19 (1977): 176-81. [PMID: 268496]
35	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
36	Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
37	Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003): E18. [PMID: 12778436]
38	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
39	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
40	Product Information. Paraplatin (carboplatin). Bristol-Myers Squibb, Princeton, NJ.
41	Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
42	Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.
43	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.